{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-003174","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.580510+00:00","generated_at":"2026-05-21T11:58:16.359853+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aptose's TUS+VEN+AZA triplet data selected for oral presentation at EHA 2025 Congress","bullets":["Data from TUSCANY Phase 1/2 trial of tuspetinib (TUS) + venetoclax + azacitidine in newly diagnosed AML accepted for oral presentation at EHA 2025 (June 12-15, Milan).","Oral presentation will include updated safety, complete remission, and MRD data at 40 mg and 80 mg dose levels with longer follow-up.","Prior data showed safety and complete remissions across diverse mutations including TP53-mutated and FLT3-wildtype patients.","TUS+VEN+AZA is being developed as mutation-agnostic frontline therapy for AML patients ineligible for induction chemotherapy.","Anticipated enrollment of 18-24 patients in TUSCANY trial by mid-late 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-003174","json":"https://secwatch.observer/filing/0001171843-25-003174.json","markdown":"https://secwatch.observer/filing/0001171843-25-003174.md","text":"https://secwatch.observer/filing/0001171843-25-003174.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325003174/0001171843-25-003174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325003174/f8k_051425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T11:58:16.359853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}